Oct 6, 2025 · Harrow is redefining the standard of care in eyecare with a portfolio of trusted, high-value pharmaceutical solutions that deliver proven safety, efficacy, and affordability.

Harrow, a leading provider of ophthalmic disease management solutions in North America, was founded with a commitment to deliver safe, effective, accessible, and affordable medications …

Harrow was established with the core principle of delivering accessible eyecare solutions to both eyecare providers and patients. We are dedicated to helping eligible patients access the …

Harrow INC SEC filing: Form 8-K iXBRL on 09/09/2025 (0001493152-25-012840).

SAN DIEGO , May 5, 2016 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the development and commercialization of proprietary …

Document Details Form 10-K Filing Date March 28, 2014 Document Date December 31, 2013 Form Description Annual report which provides a comprehensive overview of the company for …

Nov 13, 2019 · Harrow Health, Inc. (NASDAQ: HROW) owns a portfolio of healthcare businesses, including ImprimisRx, the nation’s leading ophthalmology outsourcing facility and …

I authorize Harrow, Inc., to send me SMS Texts regarding Harrow and other informational materials. I understand that I may revoke this authorization and choose not to receive …

By selectively investing in assets with reduced clinical and regulatory uncertainty and executing with a streamlined operational model, Harrow efficiently progresses products toward approval …

Dec 12, 2025 · Document Details Form 4 Filing Date December 16, 2025 Document Date December 12, 2025 Form Description Statement of changes in beneficial ownership of …